Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The X chromosome has long been an overlooked territory in Alzheimer disease (AD). Given the high density of X-linked genes expressed in the brain, exploring the X chromosome presents a compelling opportunity to uncover new genetic variations that may contribute to AD. The sex-specific nature of AD is well documented, with consistent findings of a greater prevalence of AD dementia in epidemiological cohorts, as well as higher levels of tau burden in older women relative to men, particularly in those with abnormal levels of amyloid burden. The recent study by Belloy et al, 1 published in this issue of JAMA Neurology, marks a significant advancement toward understanding the sex biological mechanisms at play by performing the first large-scale X chromosome-wide association study (XWAS) of AD dementia. Belloy et al 1 conducted an AD dementia case-control metaanalysis using genetic data from a multitude of cohorts, including the US Alzheimer's Disease Genetics Consortium (ADGC), Alzheimer's Disease Sequencing Project (ADSP), UK Biobank (UKB), the Finnish health registry (FinnGen), and the US Million Veterans Program (MVP). Their analysis, which included over 1.15 million participants, identified 6 loci with X chromosome-wide significance (P value <1 × 10 −5 ), with 4 showing causal support for an association with risk for AD. One locus, in the intron of SLC9A7 or CHST7, was of particular interest. The identified loci were involved in regulation of pH homeostasis in Golgi secretory compartments, and the authors argued that SLC9A7 may have downstream effects on β-amyloid accumulation.The X chromosome has remained enigmatic in AD research primarily due to technical challenges and complexities associated with its analysis. Traditional genome-wide association studies (GWAS) often exclude the X chromosome, focusing instead on autosomal chromosomes. In most studies, X-chromosome gene variants are discarded early in the quality control process. 2 They may also be improperly analyzed without accounting for unique issues associated with the X, such as mode of inheritance, X-chromosome inactivation escapism, 3 and consequent population genetic and evolutionary patterns. 4 This exclusion has left a gap in our understanding of sex-specific genetic contributions to AD via X-linked genes. Many human diseases, including AD, show some degree of sex specificity, which suggests an additional contribution of the X chromosome, which further highlights the major gap in the literature. Some major studies have demonstrated the importance of examining the X across a range of psychiatric and neurological conditions 5,6 ; however, the case for running an XWAS in AD dementia has remained underexplored, until now.
The X chromosome has long been an overlooked territory in Alzheimer disease (AD). Given the high density of X-linked genes expressed in the brain, exploring the X chromosome presents a compelling opportunity to uncover new genetic variations that may contribute to AD. The sex-specific nature of AD is well documented, with consistent findings of a greater prevalence of AD dementia in epidemiological cohorts, as well as higher levels of tau burden in older women relative to men, particularly in those with abnormal levels of amyloid burden. The recent study by Belloy et al, 1 published in this issue of JAMA Neurology, marks a significant advancement toward understanding the sex biological mechanisms at play by performing the first large-scale X chromosome-wide association study (XWAS) of AD dementia. Belloy et al 1 conducted an AD dementia case-control metaanalysis using genetic data from a multitude of cohorts, including the US Alzheimer's Disease Genetics Consortium (ADGC), Alzheimer's Disease Sequencing Project (ADSP), UK Biobank (UKB), the Finnish health registry (FinnGen), and the US Million Veterans Program (MVP). Their analysis, which included over 1.15 million participants, identified 6 loci with X chromosome-wide significance (P value <1 × 10 −5 ), with 4 showing causal support for an association with risk for AD. One locus, in the intron of SLC9A7 or CHST7, was of particular interest. The identified loci were involved in regulation of pH homeostasis in Golgi secretory compartments, and the authors argued that SLC9A7 may have downstream effects on β-amyloid accumulation.The X chromosome has remained enigmatic in AD research primarily due to technical challenges and complexities associated with its analysis. Traditional genome-wide association studies (GWAS) often exclude the X chromosome, focusing instead on autosomal chromosomes. In most studies, X-chromosome gene variants are discarded early in the quality control process. 2 They may also be improperly analyzed without accounting for unique issues associated with the X, such as mode of inheritance, X-chromosome inactivation escapism, 3 and consequent population genetic and evolutionary patterns. 4 This exclusion has left a gap in our understanding of sex-specific genetic contributions to AD via X-linked genes. Many human diseases, including AD, show some degree of sex specificity, which suggests an additional contribution of the X chromosome, which further highlights the major gap in the literature. Some major studies have demonstrated the importance of examining the X across a range of psychiatric and neurological conditions 5,6 ; however, the case for running an XWAS in AD dementia has remained underexplored, until now.
Due to methodological reasons, the X-chromosome has not been featured in the major genome-wide association studies on Alzheimer’s Disease (AD). To address this and better characterize the genetic landscape of AD, we performed an in-depth X-Chromosome-Wide Association Study (XWAS) in 115,841 AD cases or AD proxy cases, including 52,214 clinically-diagnosed AD cases, and 613,671 controls. We considered three approaches to account for the different X-chromosome inactivation (XCI) states in females, i.e. random XCI, skewed XCI, and escape XCI. We did not detect any genome-wide significant signals (P ≤ 5 × 10−8) but identified seven X-chromosome-wide significant loci (P ≤ 1.6 × 10−6). The index variants were common for the Xp22.32, FRMPD4, DMD and Xq25 loci, and rare for the WNK3, PJA1, and DACH2 loci. Overall, this well-powered XWAS found no genetic risk factors for AD on the non-pseudoautosomal region of the X-chromosome, but it identified suggestive signals warranting further investigations.
BackgroundPeople with Alzheimer’s disease (AD) exhibit varying clinical trajectories. There is a need to predict future AD-related outcomes such as morbidity and mortality using clinical profile at the point of care.ObjectiveTo stratify AD patients based on baseline clinical profiles (up to two years prior to AD diagnosis) and update the model after AD diagnosis to prognosticate future AD-related outcomes.MethodsUsing the electronic health record (EHR) data of a large healthcare system (2011-2022), we first identified patients with ≥1 diagnosis code for AD or related dementia and applied a validated unsupervised phenotyping algorithm to assign AD diagnosis status. Next, we applied an unsupervised latent factor clustering approach, guided by knowledge graph embeddings of relevant EHR features up to the baseline, to cluster patients into two groups at AD diagnosis. We then prognosticated the risk of two readily ascertainable and clinically relevant AD-related outcomes (i.e.,nursing home admission indicating greater need for assistance and mortality), adjusting for baseline confounders (e.g.,age, gender, race, ethnicity, healthcare utilization, and comorbidities). For patients remaining at risk one year post-diagnosis, we updated their group membership and repeated the prognostication.ResultsWe stratified 16,411 algorithm-identified AD patients into two groups based on their baseline clinical profiles (41% Group 1, 59% Group 2). Patients in Group 1 were marginally older at AD diagnosis (age Mean [SD]: 81.4 [9.3] vs 81.0 [8.7],p=.007), exhibited greater comorbidity burden (Elixhauser comorbidity index Mean [SD]: 11.3 [10.3] vs 7.5 [8.6],p<.0001), and more frequently received AD-related medications (47.7% vs 40.9%,p<.0001) than those in Group 2. Compared to Group 1, Group 2 had a lower risk of nursing home admission (HR [95% CI]=0.804 [0.765, 0.844],p<.001), while the two groups had similar mortality risk (HR [95% CI]=1.008 [0.963, 1.056],p=.733). One year after AD diagnosis, 12,606 patients remained at risk (45.7% Group 1, 54.3% Group 2). Consistent with baseline findings, Group 2 had a lower risk of nursing home admission than (HR [95% CI]=0.815 [0.766, 0.868],p<.001) and similar mortality risk as (HR [95% CI]=0.977 [0.922, 1.035],p=0.430) Group 1 in the updated model.ConclusionsIt is feasible to stratify patients based on readily available clinical profiles before AD diagnosis and crucially to update the model one year after diagnosis to effectively prognosticate future AD-related outcomes.SHORT ABSTRACTPrognostication for people with Alzheimer’s disease (AD) at the point of care could improve clinical management. Applying a novel unsupervised latent factor clustering approach guided by knowledge graph embeddings of relevant clinical features from electronic health records, we stratified 16,411 AD patients into two groups at diagnosis and prognosticated their risk of AD-related outcomes (i.e.,nursing home admission, mortality), adjusting for baseline confounders. To reflect real-world evolution in clinical trajectories, we updated patient stratification for 12,606 AD patients remaining at risk 1-year post-diagnosis and repeated prognostication. At both timepoints, one group had a higher nursing home admission risk and exhibited characteristics suggesting greater symptom burden, but the mortality risk remained comparable between groups. This study supports that patient stratification can enable outcome prognosis for AD patients. While baseline prognostication can guide early treatment and tailored management, dynamic prognostication may inform more timely interventions to improve long-term outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.